Highlights
- Institutional investors have significantly expanded their positions in Zoetis Inc. (NYSE:ZTS).
- Several firms have recently acquired additional shares, reflecting continued interest in the company.
- Zoetis remains a focal point for investment firms managing large-scale portfolios.
Institutional Interest in Zoetis Inc.
Zoetis Inc. operates within the animal health sector, developing and manufacturing medications, vaccines, and diagnostic products for livestock and companion animals. The company continues to attract substantial attention from institutional firms, with many expanding their positions.
Increased Holdings by Major Firms
Choreo LLC recently disclosed a notable increase in its holdings, adding 9,018 shares and bringing its total stake to 28,408 shares. This adjustment elevated the total value of its holdings to $4,613,000 by the end of the reporting period.
Tectonic Advisors LLC also expanded its position, growing its stake by 33.4% during the fourth quarter. The firm now holds 4,509 shares, valued at approximately $735,000. Nvwm LLC reported a sharp rise in its ownership, more than doubling its stake with a 104.1% increase, now holding 15,416 shares, valued at $2,512,000.
Additional Institutional Moves
Mirae Asset Global Investments Co. Ltd. increased its position in Zoetis by 6.7%, acquiring an additional 4,107 shares and bringing its total to 65,760 shares, valued at $10,753,000. Weaver Capital Management LLC also strengthened its stake by 45.2%, now holding 3,226 shares, worth approximately $526,000.
Osprey Private Wealth LLC similarly raised its stake by 5.6%, purchasing an additional 740 shares, which brought its total holdings to 13,945 shares, valued at $2,272,000. These figures indicate an ongoing trend of accumulation among major financial entities.
Institutional Ownership and Market Presence
Institutional firms collectively own 92.80% of Zoetis Inc. (NYSE:ZTS), underscoring the widespread interest from large-scale investment entities. This level of ownership highlights the company's standing within the animal health industry and the appeal of its long-term business strategy.
Zoetis continues to be a significant player in the sector, with its diverse product portfolio and market presence contributing to sustained interest from institutional firms. The continued adjustments in holdings by various investment firms suggest a broader trend of maintaining exposure to Zoetis within their portfolios.